-
Mashup Score: 17SGLT2s cut cardiac risk for most with T2D - Medical Republic - 2 day(s) ago
More patients get cardiac benefits from the drugs than previously thought.
Source: www.medicalrepublic.com.auCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 49Freely Filtered, a NephJC Podcast: FF 69:DUPLEX Sparsentan, it’s no Acthar Gel on Apple Podcasts - 9 day(s) ago
Show Freely Filtered, a NephJC Podcast, Ep FF 69:DUPLEX Sparsentan, it’s no Acthar Gel – 21 Apr 2024
Source: podcasts.apple.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 32
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: investor.lilly.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 136Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease - 11 day(s) ago
Correspondence to: Brendon L. Neuen, MBBS(Hons), MSc, PhD, The George Institute for Global Health, University of New South Wales, Sydney, Australia 2050. Email The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N.). Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia (B.L.N.). Division of Cardiovascular Medicine, Center for Cardiometabolic Implementation Science, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (B.L.N.,
Source: www.ahajournals.orgCategories: General Medicine News, General HCPsTweet-
How can we prioritise accelerated therapeutic implementation of the "four pillars" of GDMT for diabetes & CKD? -RASi -SGLT2i -ns-MRA -GLP-1RA @mvaduganathan @KatherineTuttl8 & I outline what an "accelerated, risk-based approach" might look like @CircAHA https://t.co/Vb6z9gAFnL https://t.co/G5O0elQgrT
-
-
Mashup Score: 32
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: investor.lilly.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 32
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: investor.lilly.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 32
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: investor.lilly.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 32
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: investor.lilly.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 136Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease - 14 day(s) ago
Correspondence to: Brendon L. Neuen, MBBS(Hons), MSc, PhD, The George Institute for Global Health, University of New South Wales, Sydney, Australia 2050. Email The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N.). Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia (B.L.N.). Division of Cardiovascular Medicine, Center for Cardiometabolic Implementation Science, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (B.L.N.,
Source: www.ahajournals.orgCategories: General Medicine News, General HCPsTweet-
How can we prioritise accelerated therapeutic implementation of the "four pillars" of GDMT for diabetes & CKD? -RASi -SGLT2i -ns-MRA -GLP-1RA @mvaduganathan @KatherineTuttl8 & I outline what an "accelerated, risk-based approach" might look like @CircAHA https://t.co/Vb6z9gAFnL https://t.co/G5O0elQgrT
-
-
Mashup Score: 133Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease - 15 day(s) ago
Correspondence to: Brendon L. Neuen, MBBS(Hons), MSc, PhD, The George Institute for Global Health, University of New South Wales, Sydney, Australia 2050. Email The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N.). Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia (B.L.N.). Division of Cardiovascular Medicine, Center for Cardiometabolic Implementation Science, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (B.L.N.,
Source: www.ahajournals.orgCategories: General Medicine News, General HCPsTweet-
How can we prioritise accelerated therapeutic implementation of the "four pillars" of GDMT for diabetes & CKD? -RASi -SGLT2i -ns-MRA -GLP-1RA @mvaduganathan @KatherineTuttl8 & I outline what an "accelerated, risk-based approach" might look like @CircAHA https://t.co/Vb6z9gAFnL https://t.co/G5O0elQgrT
-
Nice coverage of the recent SMART-C collaborative meta-analysis in @CircAHA, led by @SidPatelMD @swiviott & @TIMIStudyGroup https://t.co/z6oQDpOM82 Next SMART-C presentation at @ERAkidney: Effects of SGLT2i with & without GLP-1RA Find out more at https://t.co/K27QwVTZcS